Keywords
ACTH-secreting pituitary adenoma
Pituitary Diseases
radiotherapy
temozolomide
How to Cite
Abstract
Silent corticotroph adenomas are pituitary tumors of corticotroph lineage that are not associated with biochemical or clinical findings of hypercortisolism. We present the case of a 35-year-old male patient with a history of a non-functional pituitary macroadenoma initially diagnosed in 2007 and with the last pathology of 2018 confirming a corticotroph adenoma most likely of the densely granulated subtype. The patient has undergone 4 surgical procedures and received radiotherapy. There is positivity for ACTH in immunohistochemistry and elevation of ACTH in plasma, however, in the absence of clinical or biochemical signs of hypercortisolism, a diagnosis of a silent corticotroph adenoma was considered. The tumor has exhibited an aggressive behavior during follow-up, with invasion to surrounding structures and in the last pathology there is evidence of high proliferation. A review of the characteristics of this histological variant and the available therapeutic options is done
References
2. Mayson SE, Snyder PJ. Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol. 2014;117(3):429-36.
3. Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab. 2019;104(7):2473-89.
4. Ben-Shlomo A, Cooper O. Silent corticotroph adenomas. Pituitary. 2018;21(2):183-93.
5. Cooper O. Silent corticotroph adenomas. Pituitary. 2015;18(2):225-31.
6. Langlois F, Lim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, et al. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. 2018;21(1):32-40.
7. Osamura R. Pathology of Pituitary Tumors Update: World Health Organization New Classification 2017. AJSP: Reviews & Reports. 2017;22(4):189-95.
8. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228-43.
9. Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D. Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol. 2018;178(3):237-46.
10. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (Berl). 2013;126(1):123-35.
11. Manojlovic-Gacic E, Engström BE, Casar-Borota O. Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary. 2018;21(2):119-29.
12. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1-24.
13. Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology. 2015;101(2):87-104.
14. Delgado-López PD, Pi-Barrio J, Dueñas-Polo MT, Pascual-Llorente M, Gordón-Bolaños MC. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2018;20(10):1233-45.
15. Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Front Endocrinol. 2018;9:318.
16. Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary. 2017;20(2):261-6.
17. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, et al. Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression. J Clin Endocrinol Metab. 2010;95(11):E280-90.
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent. A copy may be reviewed here